甘肃医药
甘肅醫藥
감숙의약
Gansu Medical Journal
2014年
7期
500-503
,共4页
结直肠癌%K-ras基因突变%多药耐药%实时荧光定量PCR
結直腸癌%K-ras基因突變%多藥耐藥%實時熒光定量PCR
결직장암%K-ras기인돌변%다약내약%실시형광정량PCR
colorectal cancer%K-ras gene mutation%multidrug resistance%Real-time PCR
目的:探讨结直肠癌(CRC)中K-ras基因突变和多药耐药相关蛋白的表达及两者的关系。方法:利用免疫组织化学、实时荧光定量PCR技术检测K-ras基因及多药耐药相关蛋白在CRC中的表达。结果:结直肠癌中Pgp、Topo-II、CerbB-2、GST-π和Ki-67的阳性率分别为15.8%,84.21%,26.13%,71.42%,32.67%。 Pgp、Topo-II的表达和K-ras突变率与肿瘤发病的性别、类型、分化程度、浸润深度及有无淋巴结转移无关(P>0.05),CerbB-2、GST-π的阳性率与肿瘤淋巴结转移相关(P<0.05),Ki-67的阳性率与肿瘤浸润深度和淋巴结转移相关(P<0.05)。 K-ras基因突变率为28.94%,与CerbB-2的表达呈正相关(P<0.05)。结论:联合检测多药耐药相关蛋白及K-ras突变有助于临床判定CRC对化疗药物的敏感性、制定个性化化疗方案提供依据。
目的:探討結直腸癌(CRC)中K-ras基因突變和多藥耐藥相關蛋白的錶達及兩者的關繫。方法:利用免疫組織化學、實時熒光定量PCR技術檢測K-ras基因及多藥耐藥相關蛋白在CRC中的錶達。結果:結直腸癌中Pgp、Topo-II、CerbB-2、GST-π和Ki-67的暘性率分彆為15.8%,84.21%,26.13%,71.42%,32.67%。 Pgp、Topo-II的錶達和K-ras突變率與腫瘤髮病的性彆、類型、分化程度、浸潤深度及有無淋巴結轉移無關(P>0.05),CerbB-2、GST-π的暘性率與腫瘤淋巴結轉移相關(P<0.05),Ki-67的暘性率與腫瘤浸潤深度和淋巴結轉移相關(P<0.05)。 K-ras基因突變率為28.94%,與CerbB-2的錶達呈正相關(P<0.05)。結論:聯閤檢測多藥耐藥相關蛋白及K-ras突變有助于臨床判定CRC對化療藥物的敏感性、製定箇性化化療方案提供依據。
목적:탐토결직장암(CRC)중K-ras기인돌변화다약내약상관단백적표체급량자적관계。방법:이용면역조직화학、실시형광정량PCR기술검측K-ras기인급다약내약상관단백재CRC중적표체。결과:결직장암중Pgp、Topo-II、CerbB-2、GST-π화Ki-67적양성솔분별위15.8%,84.21%,26.13%,71.42%,32.67%。 Pgp、Topo-II적표체화K-ras돌변솔여종류발병적성별、류형、분화정도、침윤심도급유무림파결전이무관(P>0.05),CerbB-2、GST-π적양성솔여종류림파결전이상관(P<0.05),Ki-67적양성솔여종류침윤심도화림파결전이상관(P<0.05)。 K-ras기인돌변솔위28.94%,여CerbB-2적표체정정상관(P<0.05)。결론:연합검측다약내약상관단백급K-ras돌변유조우림상판정CRC대화료약물적민감성、제정개성화화료방안제공의거。
Purpose To investigate the expression of the multidrug resistance and K-ras gene mutations in the colorectal cancer and their relationship. Methods:Using Immunohistochemistry and real-time quantitative PCR technique. Results:The expression rate of Pgp , Topo-II , CerbB-2 , GST-π and Ki-67 were 15 . 8%, 84 . 21%, 26 . 13%, 71 . 42%, 32 . 67% in the colorectal cancer . The expression rate of Pgp , Topo-II and K-ras mutation was not significant (P>0 . 05) with tumor incidence of gender , type , differentiation , depth of invasion and lymph node metastasis (P>0 . 05), while CerbB-2 , GST-π was significant with lymph node metastasis (P<0 . 05), Ki-67 was significant with tumor infiltration depth and lymph node metastasis (P<0 . 05). K-ras gene mutation rate was 28 . 94%, and was positively correlated with CerbB-2 expression (P<0 . 05). Conclusion:Combined detection of multidrug resistance- associated protein and K-ras gene mutations can contribute to judgment CRC sensitivity to chemotherapeutic drugs and provide the theory to formulate personalized chemotherapy .